GLS - GLS STOCK NEWS

PureTech Health and its Founded Entity, Gelesis Holdings, presented preclinical data at the World of Microbiome Conference in Vienna. The study showed that Gelesis’ proprietary superabsorbent hydrogel, Gel-B, when added to a high-fat diet, positively influenced gut microbiota, enhancing metabolic health indicators such as weight and glucose control. Notably, Gel-B promoted increased growth of Akkermansia muciniphila, beneficial for gut health. The findings suggest Gel-B's therapeutic potential extends beyond mere space occupation in the digestive system.

Gelesis (NYSE: GLS) presented new pre-clinical data at the World of Microbiome Conference in Vienna, showing that their superabsorbent hydrogel, Gel-B, can positively alter gut bacteria communities in high-fat diets, promoting better metabolic health. The study demonstrated significant growth in Akkermansia muciniphila, a beneficial gut bacterium, suggesting Gel-B's potential beyond weight management. Researchers noted improvements in metabolic parameters and gut barrier function, indicating possible advances in obesity treatment.

Gelesis (NYSE: GLS) reported significant growth in its fiscal year 2021, with total product revenue of $11.2 million, a 313% increase from 2020. The company ended the year with 79,100 members for Plenity, reflecting strong demand. Gelesis anticipates a revenue of $58 million in 2022, projecting 400% growth driven by a national media campaign. Despite a net loss of $93.3 million, the firm has gained traction in both telehealth and healthcare provider channels. Gelesis is actively ramping up manufacturing to meet increasing demand.

Gelesis (NYSE: GLS) will announce its fiscal year 2021 financial results on March 24, 2022, after market close. Management will conduct a conference call at 4:30 p.m. ET to discuss the results, accessible via the Gelesis Investor Relations website. Gelesis develops innovative treatments like Plenity® for weight management, utilizing unique superabsorbent hydrogels. Plenity® is FDA-cleared for adults with a BMI of 25–40 kg/m², aimed at aiding weight management in conjunction with diet and exercise.

Gelesis Holdings Inc. (NYSE: GLS) announced promising preliminary results from its media campaign launched on January 31, 2022. Patient prescriptions for Plenity surged 3.5-fold within three weeks, accompanied by a threefold increase in web traffic. Gelesis anticipates $58 million in net revenue for 2022, reinforcing prior guidance. Approximately 4,700 new Plenity members joined weekly, with 70% being new to prescription weight management. Healthcare provider prescriptions doubled since the campaign's inception, showcasing a robust response to the digital-first strategy.

Gelesis (NYSE: GLS) reported a 3.5-fold increase in new Plenity patient prescriptions within three weeks of its national media campaign launch on January 31, 2022. The company anticipates $58 million in net revenue for the full launch year 2022. During this period, Gelesis acquired approximately 4,700 new Plenity members weekly and achieved web traffic growth. The media campaign has driven a 100% increase in healthcare provider prescriptions. Gelesis expects to release 2021 earnings this month, reflecting the impact of the campaign.

Gelesis Holdings (NYSE: GLS) has launched the "Who Said?" marketing campaign for Plenity, aiming to challenge cultural norms around weight loss. This campaign targets the 70% of Americans struggling with excess weight and promotes a new approach to weight management without deprivation. Plenity is FDA-cleared and uses a biomimetic method to enhance satiety, resulting in an average weight loss of 22 pounds in clinical trials. Gelesis anticipates $58 million in revenue for 2022 during its first full year post-launch.

Gelesis has launched its debut marketing campaign for Plenity, focusing on weight management. The 'Who Said?' campaign aims to challenge societal views on weight loss while promoting Plenity's FDA-cleared, non-drug solution to assist in weight management for adults with a BMI of 25-40. The company anticipates approximately $58 million in revenue for 2022, following its recent NYSE listing. With a unique telehealth offering and insights from over 20,000 members, Plenity aims to empower a projected 150 million eligible Americans to embrace sustainable weight loss.

Gelesis, known for its FDA-cleared weight management product, Plenity, has successfully completed its business combination with Capstar Special Purpose Acquisition Corp., leading to Gelesis trading under the ticker 'GLS' on the New York Stock Exchange starting January 14, 2022. The transaction raised approximately $105 million, which will primarily support the nationwide launch of Plenity. CEO Yishai Zohar highlighted the growing demand for weight management solutions, particularly after the pandemic, as 71 million Americans gained weight and over half sought to lose it.